Positive Efficacy Data in Murdoch Children’s Research Institute Urinary Tract Infection Animal Study
Highlights:
Murdoch Children’s Research Institutedata shows significant RECCE®327 (R327)
bactericidal activity againstEscherichia coliUrinary Tract Infections (UTI) in rat
model via intravenous infusion and new direct-to-bladder delivery
R327 is currently undergoing a Phase I/II UTI/Urosepsis Rapid Infusion Clinical
Trial to address needs at first patient presentation in GP and hospital settings
In 2019, >404.6m individualshad UTI’sglobally, ~80% resistant to two or more
antibiotics
Results of UTI study support potential for present Phase I/II Clinical Trial
Good results coming for patients - great to see
Ann: Murdoch Children's R327 Efficacy UTI in-vivo, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.008(1.94%) |
Mkt cap ! $109.8M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.0¢ | $10.83K | 28.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31243 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 48601 | 3 |
View Market Depth
| Last trade - 10.44am 01/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |